Mark Chacksfield KC

CALL: 1999 (England & Wales 1999, Ireland 2021*) | SILK: 2019
UPC Representative: 2025
Mark Chacksfield KC
A highly regarded silk in all IP matters, with an outstanding reputation as an innovative and responsive advocate in complex telecoms/(F)RAND, pharmaceutical and biopharmaceutical patent actions.

Mark has a preeminent reputation in multijurisdictional (F)RAND litigation, having acted in virtually all of the leading UK (F)RAND actions, including Acer & ASUS v Nokia, InterDigital v Lenovo, Nokia v Oppo, Amazon v Alcatel, Optis v Apple, Unwired Planet v Huawei, as well as the jurisdictionally important pair of Kigen and Vestel.  He recently appeared in the Supreme Court on the potentially revolutionary Emotional Perception AI case, and has been credited with the original creation of the Arrow declaration.  In the pharmaceutical/biopharmaceutical field Mark has litigated many of the world’s largest blockbuster products, including FKB v. AbbVie (adalimumab), Pfizer v Roche (bevacizumab), Actavis v Icos (tadalafil), Lilly v Genentech (IL-17A/F), and Hospira v. Genentech (trastuzumab); as well as related and complex SPC cases.

Additionally, Mark represents broadcasters, record companies, picture libraries and well-known personalities in copyright/privacy claims, as well as acting in musical copyright actions concerning substantial hits.

He is praised for his deep understanding of the law, innovative and inventive mind, and his impressive work ethic.

  • Experience

    Selected (F)RAND, Patents & SPC cases

    • Acer Inc and Asustek Computers v Nokia [2026] EWCA Civ 564, [2026] 5 WLUK 122: by this novel decision of international interest the Court of Appeal accepted Nokia’s argument that a patentee could discharge its RAND obligation by making an interim licence offer to be adjusted by arbitration. Described as ‘landmark’ by the commentators, this decision potentially paves the way for patentees to divert litigation to a global resolution by international arbitration, and substantially redraws trans-national (F)RAND litigation strategies.o Laboratorios Leon Farma v Comptroller-General of Patents [2026] EWHC 663 (Ch), [2025] 7 WLUK 1027: this case concerns the interesting and novel question of whether SPC protection is available in respect of a single product ‘A’, when that product has previously been authorised for placing on the market as part of a combination ‘A + B’. Relying on the CJEU decision in Medeva, the Hearing Officer and High Court said not, opening up a significant divergence with the approach seen in Europe, and potentially impacting on other important types of pharmaceutical products, such as enantiomers. Permission to appeal to the Court of Appeal has been sought.
    • Laboratorios Leon Farma v Comptroller-General of Patents [2026] EWHC 663 (Ch), [2025] 7 WLUK 1027: this case concerns the interesting and novel question of whether SPC protection is available in respect of a single product ‘A’, when that product has previously been authorised for placing on the market as part of a combination ‘A + B’. Relying on the CJEU decision in Medeva, the Hearing Officer and High Court said not, opening up a significant divergence with the approach seen in Europe, and potentially impacting on other important types of pharmaceutical products, such as enantiomers. Permission to appeal to the Court of Appeal has been sought.
    • Emotional Perception AI Ltd v Comptroller-General of Patents [2026] UKSC 3, [2026] Bus L.R. 411, [2026] 2 WLUK 133, [2026] RPC 6, [2026] 3 CL 108:  winning Managing IP’s European Impact Case of the Year, this groundbreaking decision has widely been described as one of the most important patent cases in the past decade, overturning 30 years of hegemony under the so-called Aerotel approach to assessing the patentability of computer implemented inventions, and likely making it substantially easier to obtain patent protection for such inventions in the future.
    • TP Link v Huawei [2026] EWHC 179 (Pat), this was the first (F)RAND interim licence case before the English Courts in which a patentee has embraced an implementer-led rate setting and agreed to enter into the interim licence. As a result, the main dispute was as to the sum which should be payable under the interim licence. In an important decision, the Court accepted Huawei’s case that the mid-point approach should generally apply, and apply here, and ordered a substantial payment in Huawei’s favour.
    • Cabo Ltd v MGA Entertainment [2025] EWHC 1451 (Ch), [2025] 6 WLUK 305, [2026] RPC 1, [2026] 4 C.L. 48: this was a very substantial case concerning allegations of the infringement of competition law, and unjustified patent threats, as well as issues in passing off, which ran for six weeks in Court. The core of the allegation was that MGA, a titan of the toy industry, took steps to crush the launch of a new product by the Claimant start-up, using threats of (inter alia) patent infringement and threats to withdraw its blockbuster LoL Surprise! toy to coerce retailers to agree not to take Cabo’s competitive product. As a result Cabo’s toy launch failed, and substantial damages were claimed. The Judgment has attracted substantial interest for its treatment of the Vertical Agreements Block Exemption Regulation and analysis of causation in threats law.
    • InterDigital Technology Corp v Lenovo Group Ltd [2024] EWCA Civ 743, [2024] RPC 24, this was the appeal from the below two FRAND rate setting decisions, and in particular focussed on the widely important arguments as to whether a Court-determined FRAND licence was limited to recovering royalites only back as far as six years, and the payment of interest on such delayed royalties.  The Court affirmed the decisions below, and established these important principles as a matter of FRAND law. In addition, the Court accepted InterDigital’s arguments that the original decision had failed properly to account for non-RAND distortions in the market, had set the lump too low sum, and increased  the total payable by Lenovo to $178 million.
    • Lenovo Group Ltd v. InterDigital Technology Corp [2024] EWHC 596 (Ch), [2024] RPC 18: this was the first case in which the Court was faced with an application by an implementer of a telecommunications standard for a so-called ‘interim licence’ pending the final determination of FRAND licence terms by the English Courts. The Court rejected Lenovo’s application and set out a number of founding principles. Indeed this to date remains the only claim for an interim injunction in which the implementer has succeeded in its defence.
    • InterDigital Technology Corp v Lenovo Group Ltd [2023] EWHC 1578 (Pat), [2023] R.P.C. 14, following on from the below decision, this judgment concerned in particular the question of interest on royalties on past sales in a FRAND licence, establishing for the first time that interest should be paid on those royalties, on the facts of this case at 4% compounded, amounting to an extra $46 million.
    • InterDigital Technology Corp v Lenovo Group Ltd [2023] EWHC 539 (Pat),[2023] EWHC 1583 (Pat), [2023] RPC 13: this very high profile judgment was the UK’s second ever FRAND rate-setting dispute, and one of only a handful world-wide, which involved both fact evidence and with, between them, the parties calling 14 separate expert witnesses on issues as diverse as valuation, foreign law, patent counting and hedonic regression analysis.  The trial ran for 5 weeks, and traversed a wide range of legal issues argued to be left open out of the FRAND judgment in Unwired Planet and the post-trial injunction decision in Apple v Optis, and has been widely reported in the legal and technical literature since.
    • Kigen (UK) Ltd v Thales DIS France SA [2022] EWHC 2846 (Pat), [2022] 11 WLUK 98: This was a jurisdictionally important case which addressed the question of when and in what circumstances an implementer of a telecommunications standard may bring a claim before the English Courts seeking the determination of the terms of a FRAND licence from a holder of standards essential patents.  Whilst jurisdiction was established in principle, the Court stayed the action unless and until the implementer gave unequivocal undertakings to take the FRAND licence on the terms settled by the Court (if offered by the implementer).
    • InterDigital Technology Corp v Lenovo Group Ltd [2022] EWHC 10 (Pat), [2022] 1 WLUK 3: this decision was the second technical trial between InterDigital and Lenovo.  The argument concerned E-TFC selection in HSUPA, and involved a technically complex analysis of the history and nature of the evolving standards at the relevant point in time.
    • Optis Cellular Technology LLC v Apple Retail [2021] EWCA Civ 1619, [2021] 11 WLUK 94: This was the appeal from one of the technical trials in the high profile Optis v Apple FRAND litigation, traversing questions of construction, obviousness, the evidential burden on infringement and with a particular focus in argument on the scope and extent of the so called ‘AgrEvo obviousness’ argument in a telecommunications context.
    • Optis Cellular Technology LLC v Apple Retail [2021] EWHC 1739 (Pat), [2022] RPC 6, The focus of this FRAND case was upon the potentially enormously important novel ‘estoppel’ defence advanced by Apple, to the effect that the alleged ‘late’ declaration by Optis’ forerunner in title to ETSI barred Optis from enforcing its patent rights in the UK.  In the light of extensive expert evidence, including on French law and the origin of the ETSI IPR Policy, and argument, the Court accepted Optis’ case on this point and Apple’s defence was dismissed.
    • Vestel Elektronik v Access Advance LLC [2020] EWCA Civ 440, [2021] 4 W.L.R. 60, [2021] F.S.R. 28: this jurisdictional appeal involved a novel attempt by an implementer of the HEVC/H.265 standard to bring a claim for a FRAND declaration against the administrator of a patent pool and a patentee therewithin. Although the action failed, it provided a road-map for implementer led cases in this jurisdiction, and has been widely applied since.
    • Optis Cellular Technology LLC v Apple Retail [2020] EWHC 2746, a successful patent validity and infringement claim brought against Apple, and opening the door to a UK FRAND determination between the parties.
    • Pfizer v F Hoffmann-La Roche AG [2019] EWHC 1520, [2019] RPC 14,  this case was the first successful defence by a patentee of an ‘Arrow’ declaration. Involving extensive questions of the law of declaratory relief and also of Belgian practice and procedure, the Court for the first time held that no declaration should be granted, and therefore refused to opine on the underlying technical issues.
    • Actavis Group PTC EFH v ICOS Corp [2019] UKSC 15, [2020] 1 ALL E.R. 213, [2019] RPC 9, the leading Supreme Court decision considering the correct approach to obviousness in UK law.
    • Eli Lilly v Genentech [2019] EWHC 387, [2019] WLUK 15, described by Arnold J as one of the most complex patent cases he had ever tried, this biopharmaceutical infringement/validity action concerned the treatment of rheumatoid arthritis and psoriasis using inhibitory antibodies to the interleukin IL-17A/F, and infringement by Lilly’s ixekizumab MAb product.  See also the parallel SPC decision [2019] EWHC 388, [2019] 3 WLUK 4.
    • Technetix v Teleste [2019] EWHC 126 (IPEC), [2019] F.S.R. 19, an IPEC validity and infringement action notable for both being the first attempt to introduce into the UK a Formstein/ensnarement defence to infringement by equivalents, and also for being a case in which Mark’s client, the Defendant, was successful having chosen not to call their own evidence in the light of the cross examination of the Claimant’s expert.
    • Chugai Pharmaceutical Co Ltd v UCB Pharma SA [2018] EWHC 2264 (Pat), [2018] 8 WLUK 232, a claim for substantial royalties under a biopharmaceutical patent licence, the resolution of which required the defence of an infringement claim of a US patent run under US patent law.
    • Fujifilm Kyowa Kirin Biologics Co Ltd v AbbVie Biotechnology [2017] EWHC 395 (Pat), the first ‘Arrow declaration’ case to have come to trial, paving the way for the subsequent explosion in interest in this novel form of relief; Mark having also appeared for Arrow in the original case. See also the related decisions: [2017] EWCA Civ 1, [2017] RPC 9; [2016] EWHC 3383, [2017] RPC 8; [2016] EWHC 2204, [2017] RPC 7.
    • Unwired Planet International Ltd v Huawei Technologies Co Ltd [2017] EWCA Civ 266, the first of the Unwired Planet cases to come to appeal, and was the subject of intense attention from the industry. Having succeeded at first instance, Unwired Planet successfully defended the judgment on appeal, paving the way for the much discussed FRAND action.

    Jurisdiction & Remedies

    • Acer Inc and Asustek Computers v Nokia [2026] EWCA Civ 564, [2026] 5 WLUK 122: by this novel decision of international interest the Court of Appeal accepted Nokia’s argument that a patentee could discharge its RAND obligation by the making of an interim licence offer to be adjusted by arbitration.  As a result the claim was to be stayed as a matter of its case management under CPR Pt 11. Described as ‘landmark’ by the commentators, this decision potentially paves the way for patentees to divert litigation to a global resolution by international arbitration, and substantially redrawing trans-national (F)RAND litigation strategies.
    • Kigen (UK) Ltd v. Thales DIS France SA [2022] EWHC 2846 (Pat), [2022] 11 WLUK 98: This was a jurisdictionally important case which addressed the question of when and in what circumstances an implementer of a telecommunications standard may bring a claim before the English Courts seeking the determination of the terms of a FRAND licence from a holder of standards essential patents.  Whilst jurisdiction was established in principle, the Court stayed the action unless and until the implementer gave unequivocal undertakings to take the FRAND licence on the terms settled by the Court (if offered by the implementer).
    • Vestel Elektronik v Access Advance LLC [2020] EWCA Civ 440, [2021] 4 W.L.R. 60 [2021] F.S.R. 28: this jurisdictional appeal involved a novel attempt by an implementer of the HEVC/H.265 standard to bring a claim for a FRAND declaration against the administrator of a patent pool and a patentee therewithin.
    • Chugai Pharmaceutical Co Ltd v UCB Pharma SA [2017] EWHC 1216 (Pat), this was an application to strike out a claim for want of subject matter jurisdiction which concerned the limits of the power of the Court to consider matters said to engage the validity of foreign patent rights.
    • Fujifilm Kyowa Kirin Biologics Co Ltd v Abbvie Biotechnology [2017] EWCA Civ 1, This was an appeal from the first instance decisions of Henry Carr J (on subject matter jurisdiction) and Arnold J (on personal jurisdiction) in litigation concerning the availability and scope of ‘Arrow declarations’ relating to the world’s largest pharmaceutical product, Humira.
  • Education & awards
    • BA in Natural Sciences, Zoology (double 1st), Clare College, Cambridge 1997; Hurst Prize for Zoology.
  • Professional memberships
    • Chancery Bar Association
    • Intellectual Property Bar Association
  • Irish Qualifications

    As part of our preparation for the UPC, Mark has been called to the Irish Bar and has registered as a UPC Representative so he is able to accept instructions on European and UPC matters.  Please contact one of the clerks to discuss how we may assist on European work

  • Hobbies & interests

    In an earlier life Mark was a keen sportsman, fencing at a national level, coming 2nd as an U20 epeeist, and once squeaking into the top 8 in the national championships. He was also a committed modern pentathlete, obtaining his Blue at Cambridge. Now, however, his exercise is mostly limited to carrying boxes of papers, an occasional run home from chambers and kicking a ball around with his three much loved children. He also remains involved in modern pentathlon, through a charity set up by Mark and two of his team mates (now with 200 supporters). He is a board member of the ENT UK Foundation, the philanthropic and fundraising arm of ENT UK, and a trustee of the Berkshire, Buckinghamshire and Oxfordshire Wildlife Trust, part of the national network of Wildlife Trusts and which employs 150 staff, looking after 85 nature reserves and four educational centres supported by 1,700 active volunteers.  As a biologist by training, Mark has had a lifelong interest in wildlife and the environment, and is trying to learn something about regenerative land use and rewilding. He also loves travel (with a limited carbon footprint), good food and music (mostly of the type with irritating repetitive beeps).

Contact Mark Chacksfield KC's clerks

Whilst barristers have a designated practice management team, all the clerks have the capacity and knowledge to assist in cases involving all counsel.

Email the clerks